Regeneron Advances REGN7508 Into Phase 3 To Tackle Cancer-Linked Blood Clots

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals (REGN) is launching a Phase 3 trial called ROXI-CAT-I to test REGN7508 for preventing cancer-associated thrombosis in adults with solid tumors receiving treatment. The study aims to show that REGN7508 can cut the risk of blood clots versus placebo, while keeping safety in line with current standards.

The main treatment is REGN7508, a lab-made antibody drug designed to block Factor XI, a protein that helps blood clot. The goal is to lower clot risk in cancer patients without causing too much bleeding, compared with an inactive placebo injection.

This is a randomized study, so patients are assigned by chance to REGN7508 or placebo in parallel groups. It is double-blind for patients, doctors, and assessors, meaning no one knows who gets which treatment, and the core aim is to test whether REGN7508 works as a preventive therapy.

The trial was first submitted on February 6, 2026, marking the formal start of the regulatory process. The most recent update was filed on February 12, 2026, confirming that the study is set to start but not yet recruiting patients, so key readouts remain several years away.

For investors, this update signals that Regeneron is moving into the high-need area of cancer-related clots, which could support a new long-term revenue stream if results are positive. It also positions REGN against emerging Factor XI rivals from large drug makers, so early safety or efficacy signals will likely drive sentiment around REGN’s valuation in the hematology and oncology space.

The study is active in setup and listed as not yet recruiting, and further details are available on the ClinicalTrials.gov portal.

To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.